desvenlafaxine; norvenlafaxine; N-desmethylvenlafaxine (Pristiq)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Pristiq (FDA approved 2008)

Indications

Dosage

  • start 50 mg PO QD; larger doses do not improve efficacy
  • Maximum dose: 400 mg QD[5]
  • can be started at therapeutic dose (50 mg QD)
  • does not require lead-in dose as dose venlafaxine

Tabs: 50, 100 mg

Pharmacokinetics

Adverse effects

Laboratory

Mechanism of action

More general terms

References

  1. Prescriber's Letter 14(2): 2007 Follow-on Drugs: Therapeutic benefit of economic burden? Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230201&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. Speroff L et al, Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: A randomized controlled trial. Obstet Gynecol 2008, 111:77 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18165395
  3. 3.0 3.1 Prescriber's Letter 15(5): 2008 Comparison of Commonly Used Antidepressants Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240509&pb=PRL (subscription needed) http://www.prescribersletter.com
  4. Prescriber's Letter 16(2): 2009 Comparison of Venlafaxine and Desvenlafaxine (Pristiq) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250202&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. 5.0 5.1 Prescriber's Letter 17(8): 2010 CHART: Comparison of Venlafaxine and Desvenlafaxine CHART: State Regulations on Generic Substitution Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260802&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 6.2 Deprecated Reference

Database